Validation of the quantitative point-of-care CareStart biosensor for assessment of G6PD activity in venous blood
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index; none of the 19 sources its claims cite is checked for support yet.
Abstract
INTRODUCTION: Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most common enzymopathy in the human population affecting an estimated 8% of the world population, especially those living in areas of past and present malaria endemicity. Decreased G6PD enzymatic activity is associated with drug-induced hemolysis and increased risk of severe neonatal hyperbilirubinemia leading to brain damage. The G6PD gene is on the X chromosome therefore mutations cause enzymatic deficiency in hemizygote males and homozygote females while the majority of heterozygous females have an intermediate activity (between 30-80% of normal) with a large distribution into the range of deficiency and normality. Current G6PD qualitative tests are unable to diagnose G6PD intermediate activities which could hinder wide use of 8-aminoquinolines for Plasmodium vivax elimination. The aim of the study was to assess the diagnostic performances of the new Carestart G6PD quantitative biosensor. METHODS: A total of 150 samples of venous blood with G6PD deficient, intermediate and normal phenotypes were collected among healthy volunteers living along the north-western Thailand-Myanmar border. Samples were analyzed by complete blood count, by gold standard spectrophotometric assay using Trinity kits and by the latest model of Carestart G6PD biosensor which analyzes both G6PD and hemoglobin. RESULTS: Bland-Altman comparison of the CareStart normalized G6PD values to that of the gold standard assay showed a strong bias in values resulting in poor area under-the-curve values for both 30% and 80% thresholds. Performing a receiver operator curve identified threshold values for the CareStart product equivalent to the 30% and 80% gold standard values with good sensitivity and specificity values, 100% and 92% (for 30% G6PD activity) and 92% and 94% (for 80% activity) respectively. CONCLUSION: The Carestart G6PD biosensor represents a significant improvement for quantitative diagnosis of G6PD deficiency over previous versions. Further improvements and validation studies are required to assess its utility for informing radical cure decisions in malaria endemic settings.
Overview
CoChat Summary
TL;DR
The CareStart quantitative G6PD biosensor was validated against gold-standard spectrophotometry in 150 venous blood samples from the Thai-Myanmar border. It showed poor AUC when equivalent 30% and 80% thresholds were assumed, but optimized thresholds gave good sensitivity and specificity, supporting improvement over qualitative tests while requiring further field validation.
Key findings
- Bland-Altman comparison showed a strong bias, with the CareStart biosensor overestimating G6PD activity at low activity; AUC was 0.52 (95% CI 0.49–0.55) at the 30% threshold and 0.91 (95% CI 0.86–0.96) at the 80% threshold when equivalent thresholds were assumed.
- Using Youden’s Index, the optimal CareStart threshold for detecting gold-standard activity <30% (2.37 IU/gHb) was 4.55 IU/gHb, with 100% sensitivity and 92% specificity; for <80% (6.33 IU/gHb), the optimal threshold was 6.10 IU/gHb, with 92% sensitivity and 94% specificity.
- Replicate correlation was R² = 0.83 for G6PD activity and R² = 0.94 for Hb; biosensor Hb agreed with CBC Hb at R² = 0.88. Median activity in normal males was 7.91 IU/gHb by spectrophotometry and 7.85 IU/gHb by CareStart.
- For females only, at the 6.10 IU/gHb threshold for 80% activity, sensitivity and specificity were reported as 90% and 92.5%, respectively.
Methods
- Targeted convenience sample of 150 healthy volunteers aged >18 years along the north-western Thailand-Myanmar border: 42 males and 108 females, aiming for approximately 50 G6PD-deficient, 50 heterozygous female, and 50 G6PD-normal volunteers.
- Venous blood was collected in K2 EDTA; CBC was performed within 8 hours, and the Trinity spectrophotometric G6PD assay and CareStart biosensor were performed the following day within 30 hours. Each sample was run in duplicate on the biosensor, which measured both Hb and G6PD activity and reported G6PD as U/gHb.
- Analysis included linear regression for replicate correlation, Bland-Altman comparison against the reference assay, ROC AUC at different activity thresholds, and Youden’s Index to identify optimal CareStart thresholds; analyses used Stata 13.0.
Limitations
- Stated by the authors: the study was performed in a laboratory setting with regulated temperature and humidity, so testing under multiple environmental conditions reflective of hot tropical climates is needed; specific validation is needed for newborns using cord blood; no cost analysis was performed because prices were unavailable at submission.
- Stated by the authors: the ideal thresholds for discriminating activities between 30% and 80% normal were “alarmingly narrow,” with a range of only 1.55 IU/gHb (4.55–6.10).
- Evident from the text: the targeted convenience sample was not population-based, and the study assessed diagnostic performance rather than clinical outcomes; the device required at least 14 μL total blood, and volumes below 5 μL gave incorrect results without an alarm.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
0 Valid · 0 Not valid · 11 Not checked · 26 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“CareStart biosensor performed poorly in detecting deficient subjects at the 30% spectrophotometric activity threshold (<2.37IU/gHb) with an AUC of 0.52.”
§ Validation of the quantitative point-of-care CareStart biosensor for assessment of G6PD activity in venous blood > Results > Clinical performances of the CareStart G6PD biosensor
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Nevertheless, using a higher activity threshold (in this case 4.55IU/gHb) maximized the sensitivity and specificity of the test for diagnosis of deficient samples with <30% activity by spectrophotometry.”
§ Validation of the quantitative point-of-care CareStart biosensor for assessment of G6PD activity in venous blood > Discussion
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“For the female population only, where discrimination of intermediate and normal activities is paramount for correct deployment of primaquine and especially tafenoquine, the sensitivity and specificity were acceptable (90% and 92.5% respectively) when a threshold of 6.10IU/gHb for 80% activity was used.”
§ Validation of the quantitative point-of-care CareStart biosensor for assessment of G6PD activity in venous blood > Discussion
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
None of the sources cited for this claim have been checked yet.
In the paper
“testing for G6PD deficiency on umbilical cord blood or very early in the neonatal period using qualitative rapid tests has been shown to be unreliable [23] because of reticulocytosis [24].”
§ Validation of the quantitative point-of-care CareStart biosensor for assessment of G6PD activity in venous blood > Introduction
What the sources say
- Not checked yetcites [23] Thielemans L, Gornsawun G, Hanboonkunupakarn B, Paw MK, Porn P, Moo PK, et al Diagnostic performances of the fluorescent spot test for G6PD deficiency in newborns along the Thailand-Myanmar border: A cohort study. Wellcome open research. 2018; 3: 1 Epub 2018/03/20. doi: 10.12688/wellcomeopenres.13373.1. 29552643 PMC5829521 source
- Not checked yetcites [24] Paterakis GS, Lykopoulou L, Papassotiriou J, Stamulakatou A, Kattamis C, Loukopoulos D. Flow-cytometric analysis of reticulocytes in normal cord blood. Acta haematologica. 1993; 90(4): 182– 5. Epub 1993/01/01. doi: 10.1159/000204454. 8140857 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Thus, quantitative G6PD tests in these populations can play a role in diagnosing G6PD deficiency more accurately in neonates.”
§ Validation of the quantitative point-of-care CareStart biosensor for assessment of G6PD activity in venous blood > Introduction
plainstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
3 more claims
Create a free account to see all 37 claims and to verify the 19 references still open.
- It may state two separate claims as one. 27
- Probably not a substantial claim. 7
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Qualitative screening cannot reliably differentiate G6PD normal patients from those having >30% to <80% of normal enzyme activity [21,22].”
In the citing paper
“Samples having hemoglobin measurements of less than 10 g/dL were excluded from further analyses in order to avoid the impact of anemia causing falsely elevated G6PD readings [22].”
Citations
Cites
Glucose-6-phosphate dehydrogenase deficiency
Cappellini, M., & Fiorelli, G. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60073-2 · Cited by 1,590
Receiver operating characteristic (ROC) curve for medical researchers
Kumar, R., & Indrayan, A. (2011) · Indian Pediatrics · doi:10.1007/s13312-011-0055-4 · Cited by 872
Howes, R. E., Piel, F. B., Patil, A. P., Nyangiri, O. A., Gething, P. W., Dewi, M., Hogg, M. M., Battle, K. E., Padilla, C. D., Baird, J. K., et al. (2012) · PLoS Medicine · doi:10.1371/journal.pmed.1001339 · Cited by 562
Beutler, E., Blume, K. G., Kaplan, J. C., Löhr, G. W., Ramot, B., & Valentine, W. N. (1977) · British Journal of Haematology · doi:10.1111/j.1365-2141.1977.tb00589.x · Cited by 533
Glucose-6-Phosphate Dehydrogenase Deficiency
Luzzatto, L., Nannelli, C., & Notaro, R. (2016) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2015.11.006 · Cited by 400
Medications and Glucose-6-Phosphate Dehydrogenase Deficiency: An Evidence-Based Review
Youngster, I., Arcavi, L., Schechmaster, R., Akayzen, Y., Popliski, H., Shimonov, J., Beig, S., & Berkovitch, M. (2010) · Drug Safety · doi:10.2165/11536520-000000000-00000 · Cited by 258
Domingo, G. J., Satyagraha, A. W., Anvikar, A., Baird, K., Bancone, G., Bansil, P., Carter, N., Cheng, Q., Culpepper, J., Eziefula, C., et al. (2013) · Malaria Journal · doi:10.1186/1475-2875-12-391 · Cited by 160
Self-citationChu, C. S., Bancone, G., Moore, K. A., Win, H. H., Thitipanawan, N., Po, C., Chowwiwat, N., Raksapraidee, R., Wilairisak, P., Phyo, A. P., et al. (2017) · PLOS Medicine · doi:10.1371/journal.pmed.1002224 · Cited by 146
Self-citationManagement of relapsing Plasmodium vivax malaria
Chu, C. S., & White, N. J. (2016) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2016.1220304 · Cited by 130
Self-citationBetuela, I., Rosanas-Urgell, A., Kiniboro, B., Stanisic, D. I., Samol, L., de Lazzari, E., del Portillo, H. A., Siba, P., Alonso, P. L., Bassat, Q., et al. (2012) · The Journal of Infectious Diseases · doi:10.1093/infdis/jis580 · Cited by 118
Cited by
Lee, H. Y., Ithnin, A., Sabudin, R. Z. A. R., Othman, A., Salvador, A., & Cheah, F. (2022) · Frontiers in Pediatrics · doi:10.3389/fped.2022.875877 · Cited by 161
The prevention and treatment of Plasmodium vivax malaria
Chu, C. S., & White, N. J. (2021) · PLOS Medicine · doi:10.1371/journal.pmed.1003561 · Cited by 88
Self-citationPal, S., Bansil, P., Bancone, G., Hrutkay, S., Kahn, M., Gornsawun, G., Penpitchaporn, P., Chu, C. S., Nosten, F., & Domingo, G. J. (2018) · The American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.18-0612 · Cited by 91
Self-citationLaboratory diagnosis of G6PD deficiency. A British Society for Haematology Guideline
Roper, D. R., Layton, M. D., Rees, D. C., Lambert, C., Vulliamy, T., la Salle, B. D., D’Souza, C., & the British Society for Haematology (2020) · British Journal of Haematology · doi:10.1111/bjh.16366 · Cited by 72
Bancone, G., Menard, D., Khim, N., Kim, S., Canier, L., Nguong, C., Phommasone, K., Mayxay, M., Dittrich, S., Vongsouvath, M., et al. (2019) · Malaria Journal · doi:10.1186/s12936-019-2652-y · Cited by 50
Self-citationTafenoquine and G6PD: A Primer for Clinicians
Chu, C. S., & Freedman, D. O. (2019) · Journal of Travel Medicine · doi:10.1093/jtm/taz023 · Cited by 63
Self-citationZobrist, S., Brito, M. A. M., Garbin, E., Monteiro, W. M., Freitas, S. C., Macedo, M., Moura, A. S., Advani, N., Kahn, M., Pal, S., et al. (2021) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0009649 · Cited by 62
Self-citationHenriques, G., Phommasone, K., Tripura, R., Peto, T. J., Raut, S., Snethlage, C. M. F., Sambo, I., Sanann, N., Nguon, C., Adhikari, B., et al. (2018) · Malaria Journal · doi:10.1186/s12936-018-2390-6 · Cited by 54
Commons, R. J., McCarthy, J. S., & Price, R. N. (2020) · The Medical Journal of Australia · doi:10.5694/mja2.50474 · Cited by 43
Point-of-Care Testing for G6PD Deficiency: Opportunities for Screening
Anderle, A., Bancone, G., Domingo, G. J., Gerth‐Guyette, E., Pal, S., & Satyagraha, A. W. (2018) · International Journal of Neonatal Screening · doi:10.3390/ijns4040034 · Cited by 42
Self-citationSadhewa, A., Cassidy-Seyoum, S. A., Acharya, S., Devine, A., Price, R. N., Mwaura, M., Thriemer, K., & Ley, B. (2023) · Pathogens · doi:10.3390/pathogens12050650 · Cited by 39
Village malaria workers for the community-based management of vivax malaria
Adhikari, B., Tripura, R., Peto, T. J., Callery, J. J., von Seidlein, L., Lek, D., & Dondorp, A. M. (2022) · The Lancet Regional Health - Southeast Asia · doi:10.1016/j.lansea.2022.100128 · Cited by 30
Adhikari, B., Awab, G. R., & von Seidlein, L. (2021) · Malaria Journal · doi:10.1186/s12936-021-03702-5 · Cited by 29
Yan, S. L. R., Wakasuqui, F., & Wrenger, C. (2020) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2020.115122 · Cited by 28
Brito-Sousa, J. D., Murta, F., Vítor-Silva, S., Sampaio, V. D. S., Mendes, M. O., Brito, M. A. M., Batista, T. S. B., Santos, A. C., Marques, L. L. G., Barbosa, L. R. A., et al. (2021) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0009415 · Cited by 23
Self-citationZailani, M. A. H., Sabudin, R. Z. A. R., Ithnin, A., Alauddin, H., Sulaiman, S. A., Ismail, E., & Othman, A. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2023.1098828 · Cited by 21
Assessing the Reliability of Commercially Available Point of Care in Various Clinical Fields
Pezzuto, F., Scarano, A., Marini, C., Rossi, G., Stocchi, R., Cerbo, A. D., & Cerbo, A. D. (2019) · The Open Public Health Journal · doi:10.2174/1874944501912010342 · Cited by 21
Lek, D., Callery, J. J., Bunreth, V., Vanna, M., Davoeung, C., Sovann, Y., You, S., Ol, S., Tripura, R., Chew, R., et al. (2024) · Malaria Journal · doi:10.1186/s12936-023-04828-4 · Cited by 20
Chu, C. S., Bancone, G., Soe, N. L., Carrara, V. I., Gornsawun, G., & Nosten, F. (2019) · Wellcome Open Research · doi:10.12688/wellcomeopenres.15100.1 · Cited by 10
Self-citationBrito-Sousa, J. D., Murta, F., Vítor-Silva, S., Sampaio, V. D. S., Mendes, M. O., Souza, B., Batista, T. S. B., Santos, A. C., Marques, L. L. G., Barbosa, L. R. A., et al. (2022) · Pathogens · doi:10.3390/pathogens11111328 · Cited by 19
Self-citationSanna, A., Lambert, Y., Maroto, I. J., Galindo, M. S., Plessis, L., Bardon, T., Carboni, C., Miller, J. B., Hiwat, H., Cairo, H., et al. (2024) · Malaria Journal · doi:10.1186/s12936-024-05040-8 · Cited by 18
Tafenoquine: the new kid on the block
Chen, V., & Daily, J. P. (2019) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000574 · Cited by 18
Impact of glucose-6-phosphate dehydrogenase deficiency on dengue infection in Myanmar children
May, W. L., Kyaw, M. P., Blacksell, S. D., Pukrittayakamee, S., Chotivanich, K., Hanboonkunupakarn, B., Thein, K. N., Lim, C. S., Thaipadungpanit, J., Althaus, T., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0209204 · Cited by 18
Assessment of CareStart G6PD rapid diagnostic test and CareStart G6PD biosensor in Mauritania
Djigo, O. K. M., Khalef, Y. O., Salem, M. S. O. A., Gomez, N., Basco, L. K., Briolant, S., & Boukhary, A. O. M. S. (2021) · Infectious Diseases of Poverty · doi:10.1186/s40249-021-00889-2 · Cited by 16
Vivax malaria in pregnancy and lactation: a long way to health equity
Brummaier, T., Gilder, M. E., Gornsawun, G., Chu, C. S., Bancone, G., Pimanpanarak, M., Chotivanich, K., Nosten, F. H., & McGready, R. M. (2020) · Malaria Journal · doi:10.1186/s12936-020-3123-1 · Cited by 16
Self-citationBancone, G., Gornsawun, G., Peerawaranun, P., Penpitchaporn, P., Paw, M. K., Poe, D. D., Win, D., Cicelia, N., Mukaka, M., Archasuksan, L., et al. (2022) · PLOS Global Public Health · doi:10.1371/journal.pgph.0000475 · Cited by 14
“G6PD genotyping for Mahidol (487G>A), the most common local variant, was performed on all samples; genotyping for the other 4 local G6PD variants, Union (1360C>T), Canton (1376G>T), Kaiping (1388G>A) and Chinese-4 (392G>T) was performed only on FST-deficient samples; established protocols were used [21, 22].”
MethodSelf-citationSatyagraha, A. W., Sadhewa, A., Panggalo, L. V., Subekti, D., Elyazar, I., Soebianto, S., Mahpud, N., Harahap, A. R., & Baird, J. K. (2021) · PLOS Neglected Tropical Diseases · doi:10.1371/journal.pntd.0009610 · Cited by 12
Taking on Plasmodium vivax malaria: A timely and important challenge
von Seidlein, L., & White, N. J. (2021) · PLoS Medicine · doi:10.1371/journal.pmed.1003593 · Cited by 11
Han, K. T., Han, Z. Y., Aye, K. H., Wai, K. T., Thi, A., Cui, L., & Sattabongkot, J. (2021) · Tropical Medicine and Health · doi:10.1186/s41182-021-00339-7 · Cited by 10
Sadhewa, A., Satyagraha, A. W., Alam, M. S., Adissu, W., Anvikar, A. R., Bancone, G., Bharti, P. K., Bhutani, V. K., Das, S., Hamid, M. M. A., et al. (2025) · PLoS neglected tropical diseases · doi:10.1371/journal.pntd.0012864 · Cited by 10
Self-citationComputerized Morphometric Analysis of Eryptosis
Jacob, S., Prasad, K., Rao, P., Kamath, A., Hegde, R. B., Baby, P. M., & Rao, R. K. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.01230 · Cited by 8
Glucose-6-phosphate dehydrogenase deficiency: a review
Ravikumar, N., & Greenfield, G. (2020) · International Journal of Medical Students · doi:10.5195/ijms.2020.637 · Cited by 7
Newborn Screening for Sickle Cell Disease and other Haemoglobinopathies
Lobitz, S., Élion, J., Colombatti, R., & Cela, E. (2019) · MDPI eBooks · doi:10.3390/books978-3-03921-615-4 · Cited by 6
Alkaabi, M., Khan, A. R., Balwi, M. A. A., Harbi, T. A., Ali, I., Alsaif, S. A., & Ali, K. (2025) · BMJ Paediatrics Open · doi:10.1136/bmjpo-2025-003987 · Cited by 4
Chae, H., Kwoun, W., Lee, J. J., & Youn, Y. (2024) · Medicine · doi:10.1097/md.0000000000038267 · Cited by 4
ASSISTÊNCIA ÀS CRIANÇAS COM DEFICIÊNCIA DE GLICOSE-6-FOSFATO DESIDROGENASE (G6PD)
Vilar, D. D. S. C., Silva, G. K. C., Santos, M. E. I., dos Santos, A. C. S., & de Aquino, D. S. (2023) · Revista Ibero-Americana de Humanidades, Ciências e Educação · doi:10.51891/rease.v9i9.11537 · Cited by 4
G6PD diaxBox: Digital image-based quantification of G6PD deficiency
Palasuwan, D., Chalidabhongse, T. H., Chancharoen, R., Palasuwan, A., Kobchaisawat, T., & Phanomchoeng, G. (2021) · Talanta · doi:10.1016/j.talanta.2021.122538 · Cited by 3
Pengsuk, N., Chamchoy, K., Duangdee, C., Satayarak, J., Saralamba, N., Nguitragool, W., & Boonyuen, U. (2025) · Pharmacology Research & Perspectives · doi:10.1002/prp2.70117 · Cited by 3
Kawulur, H. S. I., Krismawati, H., & Imaniar, C. (2020) · AIP conference proceedings · doi:10.1063/5.0017808 · Cited by 3
Development of a Diagnostic Kit for Point‐of‐Care Biosensors: Fundamentals and Applications
Vaishampayan, V., Kulabhushan, P., Dasgupta, I., Kapoor, A., & Gumfekar, S. P. (2023) · Wiley eBooks · doi:10.1002/9783527837946.ch11 · Cited by 2
Prevalence of glucose-6-phosphate dehydrogenase (G6PD) deficiency in Gia Lai Province, Vietnam
Võ, T. C., Lê, H. G., Kang, J., Nguyễn, Đ. T. D., Nguyễn, T. H., Yoo, W. G., Goo, Y., Trinh, N. T. M., Khanh, C. V., Quang, H. H., et al. (2024) · Parasitology International · doi:10.1016/j.parint.2024.102868 · Cited by 2
da Silva, F. R. M., Vizzoni, A. G., Mendes-de-Almeida, D. P., Bokel, J., de Oliveira, R. D. V. C., Siqueira, A. M., Vieira, Y. R., & Silva, S. D. C. C. (2025) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.70030 · Cited by 1
Weeratunga, P. N., Bancone, G., Ochodo, E., Pant, S., Thapa, J., & Chaplin, M. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013861 · Cited by 1
Self-citationNegash, M. T., Feleke, S. M., Lo, E. Y. Y., Nega, D., Abebe, A., Dufera, B., Kepple, D., Witherspoon, L., Shenkutie, T. T., Adamu, A., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-2128266/v1 · Cited by 1
Zailani, M. A. H., Sabudin, R. Z. A. R., Abdullah‐Zawawi, M., Ithnin, A., Alauddin, H., Sulaiman, S. A., Ayub, N. A., Albert, R. A., Jamaludin, M. D. A., Zapri, M. Z. M., et al. (2025) · PLoS ONE · doi:10.1371/journal.pone.0334185 · Cited by 1
Unnikrishnan, G., & Singh, A. (2026) · Tropical Medicine & International Health · doi:10.1111/tmi.70108 · Cited by 1
Tantular, I. S. (2019) · Indonesian Journal of Tropical and Infectious Disease · doi:10.20473/ijtid.v7i6.13454 · Cited by 1
Adhikari, B., Awab, G. R., & von Seidlein, L. (2021) · Figshare · doi:10.6084/m9.figshare.14302875
Adhikari, B., Awab, G. R., & von Seidlein, L. (2021) · Figshare · doi:10.6084/m9.figshare.14302878
Dysoley, L., Callery, J. J., Bunreth, V., Vanna, M., Davoeung, C., Sovann, Y., You, S., Ol, S., Tripura, R., Chew, R., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26658394
Dysoley, L., Callery, J. J., Bunreth, V., Vanna, M., Davoeung, C., Sovann, Y., You, S., Ol, S., Tripura, R., Chew, R., et al. (2024) · Figshare · doi:10.6084/m9.figshare.24934093
Dysoley, L., Callery, J. J., Bunreth, V., Vanna, M., Davoeung, C., Sovann, Y., You, S., Ol, S., Tripura, R., Chew, R., et al. (2024) · Figshare · doi:10.6084/m9.figshare.24934565
Tafenoquine lactation pharmacokinetics: a pilot study
Gilder, M. E., Wattanakul, T., Tärning, J., Hanpithakpong, W., Niwetphongprai, L., Chu, C. S., Gornsawun, G., Tawantochai, W., Heet, E., Jittamala, P., et al. (2025) · Malaria Journal · doi:10.1186/s12936-025-05685-z
Self-citationSub-RDT Plasmodium vivax infections and G6PD deficiency in Kayin State, Myanmar
Thu, A. M., Phyo, A. P., Pateekham, C., Blu, S. H., Thwin, M. M., Kajeechiwa, L., Watthanaworawit, W., Okkararungrot, Y., Bancone, G., Gornsawun, G., et al. (2026) · Malaria Journal · doi:10.1186/s12936-026-05952-7
Self-citationNegash, M. T., Golassa, L., Feleke, S. M., Lo, E. Y. Y., Nega, D., Kepple, D., Witherspoon, L., Tasew, G., Shenkutie, T. T., Adamu, A., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1637812/v1
Primaquine for Plasmodium vivax malaria treatment – Authors' reply
Price, R. N., Taylor, W. R. J., Thriemer, K., White, N. J., & Day, N. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30217-8
Taha, R. O., Youngvises, N., Pochairach, R., Phompradit, P., & Na‐Bangchang, K. (2025) · Biosensors · doi:10.3390/bios15090577
Zailani, M. A. H., Sabudin, R. Z. A. R., Ismail, A., Basri, M. B., Ithnin, A., Alauddin, H., Sulaiman, S. A., & Othman, A. (2025) · Medicine · doi:10.1097/md.0000000000045148
An Account of G6PD Deficiency Across the Geographic Boundaries- A Meta-Analysis
Pramanik, M., Kumari, N., Paul, A., Khan, S., Kundu, S., & Rudra, T. (2025) · doi:10.52756/lbsopf.2025.v04.006
Silva, F. R. D. O. [. (2022) · Arca - Repositório Institucional da Fiocruz
Study of Glucose-6-Phosphate Dehydrogenase Deficiency in Azerbaijan Population
Valiyeva, G. (. (2024) · Neliti
Nankya, W. (2026) · IAA Journal of Biological Sciences · doi:10.59298/iaajb/2026/1416574
Diagnostic Approach to Non-spherocytic Haemolytic Anaemia (NSHA)
Rani, P., & Kotru, M. (2026) · Springer eBooks · doi:10.1007/978-981-92-1167-8_4
Yu, Z., Xiong, Q., Wang, Z., Li, L., & Niu, T. (2025) · Frontiers in Genetics · doi:10.3389/fgene.2025.1593728 · Cited by 21
Metadata
- Authors
- Bancone, G., Gornsawun, G., Chu, C. S., Porn, P., Pal, S., Bansil, P., Domingo, G. J., & Nosten, F.
- Affiliations
- Mahidol University (TH)
- Program for Appropriate Technology in Health (US)
- Corresponding author
- Bancone, Germana
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2018-05-08
- Volume
- 13
- Issue
- 5
- Pages
- e0196716
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC5940185
- OpenAlex
- W2802195192
- Semantic Scholar
- 08256ddb3f46de91cb36b97964a2f9f551d89a13
- Cited by
- 65
- References
- 32
- Citations by year
- 2026: 4 · 2025: 10 · 2024: 8 · 2023: 4 · 2022: 7 · 2021: 12 · 2020: 8 · 2019: 9 · 2018: 3
- FWCI
- 7.47
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Oxford University Research Archive (ORA) (University of Oxford) (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Greater South Information System
- Funders
- Bill and Melinda Gates Foundation (OPP1034534)
- Department for International Development, UK Government (204139)
- Topics
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Neonatal Health and Biochemistry
- Health Sciences › Health Professions › Medical Laboratory Technology › Clinical Laboratory Practices and Quality Control
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Malaria Research and Control
- Keywords
- glucose-6-phosphate dehydrogenase deficiency, G6PD activity, point-of-care testing, quantitative diagnosis, diagnostic accuracy, Plasmodium vivax, 8-aminoquinolines, hemolysis, neonatal hyperbilirubinemia
- MeSH terms
- Adult, Aminoquinolines, Antimalarials, Myanmar, Clinical Enzyme Tests, Ethnicity, Female, Genotype, Glucosephosphate Dehydrogenase, Glucosephosphate Dehydrogenase Deficiency, Hemoglobinometry, Humans, Male, Methemoglobinemia, Pregnancy, Pregnancy Complications, Hematologic, Primaquine, ROC Curve, Spectrophotometry, Ultraviolet, Biosensing Techniques, Malaria, Vivax, Point-of-Care Systems, Endemic Diseases, Area Under Curve
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-21, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-21 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.